Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells

Oncogene volume 36, pages 4619–4628 (2017)Cite this article

Subjects

Abstract

B-cell CLL/lymphoma 6 (BCL6) exerts oncogenic effects in several human hematopoietic malignancies including chronic myeloid leukemia (CML), where BCL6 expression was shown to be essential for CML stem cell survival and self-renewal during imatinib mesylate (IM) treatment. As several lines of evidence suggest that interferon γ (IFNγ) production in CML patients might have a central role in the response to tyrosine kinase inhibitor (TKI) therapy, we analyzed if IFNγ modulates BCL6 expression in CML cells. Although separate IFNγ or IM treatment only slightly upregulated BCL6 expression, combined treatment induced remarkable BCL6 upregulation in CML lines and primary human CD34+ CML stem cells. We proved that during combined treatment, inhibition of constitutive signal transducer and activator of transcription (STAT) 5 activation by IM allowed the specific enhancement of the STAT1 dependent, direct upregulation of BCL6 by IFNγ in CML cells. By using colony-forming assay, we found that IFNγ enhanced the ex vivo colony or cluster-forming capacity of human CML stem cells in the absence or presence of IM, respectively. Furthermore, inhibition of the transcriptional repressor function of BCL6 in the presence of IM and IFNγ almost completely blocked the cluster formation of human CML stem cells. On the other hand, by using small interfering RNA knockdown of BCL6, we demonstrated that in an IM-treated CML line the antiapoptotic effect of IFNγ was independent of BCL6 upregulation. We found that IFNγ also upregulated several antiapoptotic members of the BCL2 and BIRC gene families in CML cells, including the long isoform of MCL1, which proved to be essential for the antiapoptotic effect of IFNγ in an IM-treated CML line. Our results suggest that combination of TKIs with BCL6 and MCL1 inhibitors may potentially lead to the complete eradication of CML stem cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Chomel JC, Turhan AG . Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. Oncotarget 2011; 2: 713–727.

    Article  Google Scholar 

  2. O’Hare T, Zabriskie MS, Eiring AM, Deininger MW . Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513–526.

    Article  Google Scholar 

  3. Basso K, Dalla-Favera R . BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol 2010; 105: 193–210.

    Article  CAS  Google Scholar 

  4. Basso K, Dalla-Favera R . Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 2012; 247: 172–183.

    Article  Google Scholar 

  5. Bunting KL, Melnick AM . New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. Curr Opin Immunol 2013; 25: 339–346.

    Article  CAS  Google Scholar 

  6. Kurosu T, Fukuda T, Miki T, Miura O . BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. Oncogene 2003; 22: 4459–4468.

    Article  CAS  Google Scholar 

  7. Tsuyama N, Danjoh I, Otsuyama K, Obata M, Tahara H, Ohta T et al. IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3. Biochem Biophys Res Commun 2005; 337: 201–208.

    Article  CAS  Google Scholar 

  8. Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G et al. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood 2010; 115: 3772–3775.

    Article  CAS  Google Scholar 

  9. Green MR, Vicente-Dueñas C, Romero-Camarero I, Long Liu C, Dai B, González-Herrero I et al. Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nat Commun 2014; 5: 3904.

    Article  CAS  Google Scholar 

  10. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011; 473: 384–388.

    Article  CAS  Google Scholar 

  11. Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 2011; 208: 2163–2174.

    Article  CAS  Google Scholar 

  12. Boehm U, Klamp T, Groot M, Howard JC . Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15: 749–795.

    Article  CAS  Google Scholar 

  13. Schroder K, Hertzog PJ, Ravasi T, Hume DA . Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163–189.

    Article  CAS  Google Scholar 

  14. Dunn GP, Koebel CM, Schreiber RD . Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836–848.

    Article  CAS  Google Scholar 

  15. Held SAE, Heine A, Kesper AR, Schönberg K, Beckers A, Wolf D et al. Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors. OncoImmunology 2016; 5: e1065368.

    Article  Google Scholar 

  16. Aswald JM, Lipton JH, Aswald S, Messner HA . Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines Cell Mol Ther 2002; 7: 143–149.

    Article  CAS  Google Scholar 

  17. Kim DH, Kong JH, Byeun JY, Jung CW, Xu W, Liu X et al. The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2010; 16: 5339–5350.

    Article  CAS  Google Scholar 

  18. Zhou G, Ono SJ . Induction of BCL-6 gene expression by interferon-gamma and identification of an IRE in exon I. Exp Mol Pathol 2005; 78: 25–35.

    Article  CAS  Google Scholar 

  19. Lee SK, Silva DG, Martin JL, Pratama A, Hu X, Chang PP et al. Interferon-γ excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity 2012; 37: 880–892.

    Article  CAS  Google Scholar 

  20. Huang BB, Bonish BK, Chaturvedi V, Qin JZ, Nickoloff BJ . Keratinocyte CDw60 expression is modulated by both a Th-1 type cytokine IFN-gamma and Th-2 cytokines IL-4 and IL-13: relevance to psoriasis. J Invest Dermatol 2001; 116: 305–312.

    Article  CAS  Google Scholar 

  21. Ohashi K, Miki T, Hirosawa S, Aoki N . Characterization of the promoter region of human BCL-6 gene. Biochem Biophys Res Commun 1995; 214: 461–467.

    Article  CAS  Google Scholar 

  22. Walker SR, Nelson EA, Frank DA . STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene 2007; 26: 224–233.

    Article  CAS  Google Scholar 

  23. Gough DJ, Levy DE, Johnstone RW, Clarke CJ . IFNgamma signaling-does it mean JAK-STAT? Cytokine Growth Factor Rev 2008; 19: 383–394.

    Article  CAS  Google Scholar 

  24. Warsch W, Walz C, Sexl V . JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood 2013; 122: 2167–2175.

    Article  CAS  Google Scholar 

  25. Mandal PK, Morlacchi P, Knight JM, Link TM, Lee GR IV, Nurieva R et al. Targeting the Src homology 2 (SH2) domain of signal transducer and activator of transcription 6 (STAT6) with cell-permeable, phosphatase-stable phosphopeptide mimics potently inhibits Tyr641 phosphorylation and transcriptional activity. J Med Chem 2015; 58: 8970–8984.

    Article  CAS  Google Scholar 

  26. Jaras M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA 2010; 107: 16280–16285.

    Article  CAS  Google Scholar 

  27. Petzer AL, Zandstra PW, Piret JM, Eaves CJ . Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin. J Exp Med 1996; 183: 2551–2558.

    Article  CAS  Google Scholar 

  28. Schürch C, Riether C, Amrein MA, Ochsenbein AF . Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ. J Exp Med 2013; 210: 605–621.

    Article  Google Scholar 

  29. Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL et al. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. J Clin Invest 2016; 126: 3351–3362.

    Article  Google Scholar 

  30. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907–14912.

    Article  CAS  Google Scholar 

  31. Youle RJ, Strasser A . The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47–59.

    Article  CAS  Google Scholar 

  32. Srinivasula SM, Ashwell JD . IAPs: what’s in a name? Mol Cell 2008; 30: 123–135.

    Article  CAS  Google Scholar 

  33. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303–3311.

    Article  CAS  Google Scholar 

  34. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307: 1101–1104.

    Article  CAS  Google Scholar 

  35. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 2015; 6: e1590.

    Article  CAS  Google Scholar 

  36. Walker SR, Nelson EA, Yeh JE, Pinello L, Yuan GC, Frank DA . STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6. Mol Cell Biol 2013; 33: 2879–2890.

    Article  CAS  Google Scholar 

  37. Ritz O, Rommel K, Dorsch K, Kelsch E, Melzner J, Buck M et al. STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL). Oncotarget 2013; 4: 1093–1102.

    Article  Google Scholar 

  38. Nakayamada S, Poholek AC, Lu KT, Takahashi H, Kato M, Iwata S et al. Type I IFN induces binding of STAT1 to Bcl6: divergent roles of STAT family transcription factors in the T follicular helper cell genetic program. J Immunol 2014; 192: 2156–2166.

    Article  CAS  Google Scholar 

  39. Fernández de Mattos S, Essafi A, Soeiro I, Pietersen AM, Birkenkamp KU, Edwards CS et al. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol 2004; 24: 10058–10071.

    Article  Google Scholar 

  40. Bonmort M, Ullrich E, Mignot G, Jacobs B, Chaput N, Zitvogel L . Interferon-gamma is produced by another player of innate immune responses: the interferon-producing killer dendritic cell (IKDC). Biochimie 2007; 89: 872–877.

    Article  CAS  Google Scholar 

  41. Zoubir M, Tursz T, Ménard C, Zitvogel L, Chaput N . Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties. Endocr Metab Immune Disord Drug Targets 2010; 10: 1–7.

    Article  CAS  Google Scholar 

  42. Krusch M, Salih HR . Effects of BCR-ABL inhibitors on anti-tumor immunity. Curr Med Chem 2011; 18: 5174–5184.

    Article  CAS  Google Scholar 

  43. Christiansson L, Söderlund S, Mangsbo S, Hjorth-Hansen H, Höglund M, Markevärn B et al. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther 2015; 14: 1181–1191.

    Article  CAS  Google Scholar 

  44. Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. Nature 2015; 525: 380–383.

    Article  CAS  Google Scholar 

  45. Cunard R, Eto Y, Muljadi JT, Glass CK, Kelly CJ, Ricote M . Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J Immunol 2004; 172: 7530–7536.

    Article  CAS  Google Scholar 

  46. Zhang X, Rodriguez-Galán MC, Subleski JJ, Ortaldo JR, Hodge DL, Wang JM et al. Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells. Blood 2004; 104: 3276–3284.

    Article  CAS  Google Scholar 

  47. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011; 117: 3421–3429.

    Article  CAS  Google Scholar 

  48. Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Hölbl A et al. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011; 117: 3409–3420.

    Article  CAS  Google Scholar 

  49. Kubonishi I, Miyoshi I . Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. Int J Cell Cloning 1983; 1: 105–117.

    Article  CAS  Google Scholar 

  50. Di Noto R, Luciano L, Lo Pardo C, Ferrara F, Frigeri F, Mercuro O et al. JURL-MK1 (c-kit(high)/CD30-/CD40-) and JURL-MK2 (c-kit(low)/CD30+/CD40+) cell lines: ‘two-sided’ model for investigating leukemic megakaryocytopoiesis. Leukemia 1997; 11: 1554–1564.

    Article  CAS  Google Scholar 

  51. Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P . Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res 1968; 28: 1300–1310.

    CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the the Swedish Cancer Society (Cancerfonden), Adolf H Lundin Charitable Foundation and Karolinska Institutet. HM, NN, TK and DS are or were recipients of Cancer Research Fellowship of the Cancer Research Institute (New York)/Concern Foundation (Los Angeles).

Author information

Authors and Affiliations

  1. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

    H S Madapura, N Nagy, T Kallas, M C L Kröhnke, S Amu, M Keszei, L S Westerberg, G Klein, E Klein & D Salamon

  2. Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden

    D Ujvari & D Salamon

  3. Division of Hematology, Department of Medicine, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden

    M Björkholm & L Stenke

  4. Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

    P K Mandal & J S McMurray

  5. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA

    H Cheng & F Xue

Authors
  1. H S Madapura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Ujvari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Kallas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M C L Kröhnke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Amu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Björkholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Stenke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P K Mandal
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J S McMurray
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Keszei
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. L S Westerberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. H Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. F Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. G Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. E Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. D Salamon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Salamon.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Madapura, H., Nagy, N., Ujvari, D. et al. Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells. Oncogene 36, 4619–4628 (2017). https://doi.org/10.1038/onc.2017.85

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2017.85

This article is cited by

Search

Advanced search

Quick links